Bayer will pay up to $600 for the 59.2% stake in engineered-cell therapy developer BlueRock Therapeutics it does now own, following a $225m round in 2016.

Pharmaceutical and chemical producer Bayer acquired US-based stem cell treatment developer and portfolio company BlueRock Therapeutics yesterday in a deal that could value it at up to $1bn. BlueRock is looking to engineer stem cells using its proprietary induced stem cell (iPSC) platform in order to treat neurological, immunological and heart diseases. Its drug candidates…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.